FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans
Psychedelic drug developer MindMed today announced that the FDA has granted breakthrough therapy designation to its LSD candidate (MM120) for the treatment of generalised anxiety disorder (GAD). The company also shared topline 12-week data from the same program, as well as results of a pharmacokinetic bridging study and further details on phase 3 study design...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In